M&A Deal Summary

H. Lundbeck Acquires Longboard Pharmaceuticals

On October 14, 2024, H. Lundbeck acquired life science company Longboard Pharmaceuticals from HBM Partners AG for 2.6B USD

Acquisition Highlights
  • This is H. Lundbeck’s 6th transaction in the Life Science sector.
  • This is H. Lundbeck’s largest (disclosed) transaction.
  • This is H. Lundbeck’s 5th transaction in the United States.
  • This is H. Lundbeck’s 2nd transaction in California.

M&A Deal Summary
Date 2024-10-14
Target Longboard Pharmaceuticals
Sector Life Science
Buyer(s) H. Lundbeck
Sellers(s) HBM Partners AG
Deal Type Add-on Acquisition
Deal Value 2.6B USD
Advisor(s) Evercore Group
Centerview Partners (Financial)
Cooley (Legal)

Target

Longboard Pharmaceuticals

La Jolla, California, United States
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals was founded in 2020 and is based in La Jolla, California.

Search 200,577 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

H. Lundbeck

Valby, Denmark
Category Company
Founded 1915
Sector Healthcare Services
Employees5,681
Revenue 19.9B DKK (2023)
DESCRIPTION

H. Lundbeck A/S is an international pharmaceutical company engaged inthe research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. H. Lundbeck was founded in 1915 and is based in Valby, Denmark.

DEAL STATS #
Overall 6 of 6
Sector (Life Science) 6 of 6
Type (Add-on Acquisition) 5 of 5
State (California) 2 of 2
Country (United States) 5 of 5
Year (2024) 1 of 1
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-16 Alder Biopharmaceuticals

Bothell, Washington, United States

Alder Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel antibodies that originate from its proprietary platform for the production of antibodies in picchia. Alder Biopharmaceuticals was formed in 2002 and is based in Bothell, Washington.

Buy $2.0B

Seller(S) 1

SELLER

HBM Partners AG

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2001
PE ASSETS 3.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.

DEAL STATS #
Overall 35 of 35
Sector (Life Science) 32 of 32
Type (Add-on Acquisition) 5 of 5
State (California) 9 of 9
Country (United States) 27 of 27
Year (2024) 3 of 3
Size (of disclosed) 3 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-10-14 Gynesonics

Redwood City, California, United States

Gynesonics is a medical device company, develops minimally invasive therapeutic device to treat uterine fibroids in women. Gynesonics was founded in 2005 and is based in Redwood City, California.

Sell $350M
Mergr

Product

Company

Legal